Collegium Pharmaceutical (COLL) Cash from Investing Activities (2015 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Cash from Investing Activities of $1.6 million for Q1 2026, up 116.81% year-over-year from $750434.1 in Q1 2025, and up 108.11% quarter-over-quarter from -$20.1 million in Q4 2025.
Collegium Pharmaceutical (COLL) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Collegium Pharmaceutical's Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 116.81% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at -$52.2 million (up 81.3% YoY), while the FY2025 annual figure was -$63.5 million, up 77.92% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $1.6 million, up from -$20.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.6 million in Q1 2026, with the low at -$572.2 million in Q1 2022.
- The 5-year median for Cash from Investing Activities is -$9.7 million (2025), against an average of -$58.5 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities slumped 133586.21% in 2022, then jumped 116.81% in 2026.
- Collegium Pharmaceutical's Cash from Investing Activities stood at -$940000.0 in 2022, then sank by 2569.89% to -$25.1 million in 2023, then jumped by 53.13% to -$11.8 million in 2024, then plunged by 70.63% to -$20.1 million in 2025, then soared by 108.11% to $1.6 million in 2026.
- Business Quant data shows COLL's Cash from Investing Activities at $1.6 million in Q1 2026, -$20.1 million in Q4 2025, and -$30.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Collegium Pharmaceutical | 887.15 Mn | 737.84 Mn | 110.29 Mn | -502.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -502.59 Mn |
| Jun 30, 2026 | -502.59 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | -20.07 Mn |
| Dec 31, 2025 | -20.07 Mn |
| Sep 30, 2025 | -30.87 Mn |
| Sep 30, 2025 | -30.87 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Mar 31, 2025 | -9.68 Mn |
| Mar 31, 2025 | -9.68 Mn |
| Dec 31, 2024 | -11.76 Mn |
| Dec 31, 2024 | -11.76 Mn |
| Sep 30, 2024 | -248.96 Mn |
| Sep 30, 2024 | -248.96 Mn |
| Jun 30, 2024 | -8.91 Mn |
| Jun 30, 2024 | -8.91 Mn |
| Mar 31, 2024 | -18.13 Mn |
| Mar 31, 2024 | -18.13 Mn |